Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 Plus Pembrolizumab vs Standard of Care in Advanced NSCLC
NCT05096663Phase 3Active, not recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of nogapendekin alfa in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Started Mar 2022; status: active, not recruiting.
02
Drugs
nogapendekin alfa
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05096663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05096663.